Literature DB >> 16219709

Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission.

R Landewé1, D van der Heijde, S van der Linden, M Boers.   

Abstract

OBJECTIVE: To compare 28 joint disease activity score (DAS28) remission with comprehensive joint count DAS remission in rheumatoid arthritis.
METHODS: 620 actually measured paired observations of DAS28 and DAS were analysed in 155 patients. Discordant observations (either DAS or DAS28 below remission cut off level: 1.6 for DAS and 2.6 for DAS28) and concordant observations (both DAS and DAS28 below their remission cut off level) were analysed separately.
RESULTS: 91 of 620 paired DAS observations (15%) were discordant; 87 (in 53 patients) comprised observations in which the DAS28 remission criterion, but not the DAS remission criterion, was met. The reverse was found in only four observations, which were therefore omitted. With the original DAS as standard, DAS28 sensitivity was 95% and specificity 84%. Probability plots showed a swollen joint count >0 in 75% of discordant pairs v 48% of concordant pairs. The same was found for total joint count (TJC >0 in 90% v 40%; median TJC, 0 v 6) and patient global assessment, but not for ESR. Individual joint analysis showed that 51% of discordant v 18% of concordant observations (p<0.0005) had involvement of lower extremity joints that are not included in the DAS28.
CONCLUSIONS: DAS remission is more conservative than DAS28 remission. Activity (tenderness and swelling) in joints not included in the reduced joint counts (ankles, feet) mainly account for the discrepancy between the two assessments. DAS28 remission at a cut off level of 2.6 has insufficient construct validity and should be used with caution in clinical practice and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219709      PMCID: PMC1798155          DOI: 10.1136/ard.2005.039859

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.

Authors:  Robert B M Landewé; Maarten Boers; Arco C Verhoeven; Rene Westhovens; Mart A F J van de Laar; Harry M Markusse; J Christiaan van Denderen; Marie Louise Westedt; Andre J Peeters; Ben A C Dijkmans; Piet Jacobs; Annelies Boonen; Désirée M F M van der Heijde; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2002-02

2.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

3.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

4.  World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

Authors:  M Boers; P Tugwell; D T Felson; P L van Riel; J R Kirwan; J P Edmonds; J S Smolen; N Khaltaev; K D Muirden
Journal:  J Rheumatol Suppl       Date:  1994-09

5.  Development of a disease activity score based on judgment in clinical practice by rheumatologists.

Authors:  D M van der Heijde; M van 't Hof; P L van Riel; L B van de Putte
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

6.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

7.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score.

Authors:  M L Prevoo; A M van Gestel; M A van T Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Br J Rheumatol       Date:  1996-11

8.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

9.  Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.

Authors:  J Fransen; M C W Creemers; P L C M Van Riel
Journal:  Rheumatology (Oxford)       Date:  2004-07-06       Impact factor: 7.580

10.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

Authors:  A M van Gestel; M L Prevoo; M A van 't Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1996-01
View more
  39 in total

Review 1.  Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review.

Authors:  Lilian H D van Tuyl; David T Felson; George Wells; Josef Smolen; Bin Zhang; Maarten Boers
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-01-15       Impact factor: 4.794

2.  Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.

Authors:  Siri Lillegraven; Nina Paulshus Sundlisæter; Anna-Birgitte Aga; Joseph Sexton; Inge C Olsen; Hallvard Fremstad; Cristina Spada; Tor Magne Madland; Christian A Høili; Gunnstein Bakland; Åse Lexberg; Inger Johanne Widding Hansen; Inger Myrnes Hansen; Hilde Haukeland; Maud-Kristine Aga Ljoså; Ellen Moholt; Till Uhlig; Daniel H Solomon; Désirée van der Heijde; Tore K Kvien; Espen A Haavardsholm
Journal:  JAMA       Date:  2021-05-04       Impact factor: 56.272

3.  Foot pain in rheumatoid arthritis prevalence, risk factors and management: an epidemiological study.

Authors:  Simon J Otter; Kevin Lucas; Kate Springett; Ann Moore; Kevin Davies; Liz Cheek; Adam Young; Karen Walker-Bone
Journal:  Clin Rheumatol       Date:  2009-12-08       Impact factor: 2.980

Review 4.  Outcome assessments in rheumatoid arthritis.

Authors:  Katarzyna Gilek-Seibert; Kara Prescott; Salahuddin Kazi
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

5.  Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome.

Authors:  C Fiehn; S Kessler; W Drexler; H M Lorenz
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

6.  Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis?

Authors:  James Woodburn; Kym Hennessy; Martijn Pm Steultjens; Iain B McInnes; Deborah E Turner
Journal:  J Foot Ankle Res       Date:  2010-05-17       Impact factor: 2.303

7.  Patterns of magnetic resonance imaging of the foot in rheumatoid arthritis: which joints are most frequently involved?

Authors:  Christian Buchbender; Axel Scherer; Falk Miese; Philipp Sewerin; Alexandra Haferkamp; Ralph Brinks; Hans-Joerg Wittsack; Gerald Antoch; Matthias Schneider; Benedikt Ostendorf
Journal:  Rheumatol Int       Date:  2013-01-03       Impact factor: 2.631

Review 8.  Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference.

Authors:  Lilian H D van Tuyl; Steven C Vlad; David T Felson; George Wells; Maarten Boers
Journal:  Arthritis Rheum       Date:  2009-05-15

9.  Forefoot disease activity in rheumatoid arthritis patients in remission: results of a cohort study.

Authors:  Marike van der Leeden; Martijn Pm Steultjens; Dirkjan van Schaardenburg; Joost Dekker
Journal:  Arthritis Res Ther       Date:  2010-01-07       Impact factor: 5.156

10.  The impact of rheumatoid foot on disability in Colombian patients with rheumatoid arthritis.

Authors:  Adriana Rojas-Villarraga; Javier Bayona; Natalia Zuluaga; Santiago Mejia; Maria-Eugenia Hincapie; Juan-Manuel Anaya
Journal:  BMC Musculoskelet Disord       Date:  2009-06-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.